Clinical Trials
Diabetic Macular Edema
Active Studies
AMARONE (Eyebiotech)
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD)
PAGODA (Genentech)
A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA.
Completed Studies
BOULEVARD (Genentech)
A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema.
DEL MAR (Allegro)
A 6 month, phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin in the treatment of diabetic macular edema.ENDURANCE IIT (NCRVA & Regeneron)
A 2 year investigator initiated study on the long-term efficacy and safety of intravitreal aflibercept (Eylea) injections for the treatment of diabetic macular edema in subjects who completed the three year VISTA-DME trial.GLIMMER (Kodiak)
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
HULK (NCRVA and Regeneron)
A phase I/II, 6 month, open label study of the safety and efficacy of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept for the treatment of diabetic macular edema.KALAHARI (Oxurion)
A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME).
KESTREL CRTH258B2301 (Novartis)
A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema.
KSI-CL-101 (Kodiak Sciences)
A Phase 1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with wet Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.
PALADIN (Alimera)
A 3 year, phase 4 safety study of IOP signals in patients with DME who are treated with ILUVIEN (fluocinolone acetonide intravitreal implant).
PALM (Allergan)
A phase 2, six month study on the evaluation of Abidipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema.PROTOCOL U (DRCR Network)
A short-term (9 months) evaluation of combination corticosteroid (Ozurdex) + Anti-VEGF (Lucentis) Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy.RHINE GR40398 (Roche)
A phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema.
RHONE (Roche)
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA.